Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

1(25%)

Phase Distribution

Ph phase_2

25%

Ph phase_1

75%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

3(75.0%)

Phase 2Efficacy & side effects

1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(2)

Detailed Status

Completed2

Terminated1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 2

Trials by Phase

Phase 13 (75.0%)

Phase 21 (25.0%)

Trials by Status

completed250%

terminated125%

withdrawn125%

Recent Activity

0 active trials

Showing 4 of 4

completedphase_2

A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2

NCT05737940

terminatedphase_1

AZD3427 Effects on Renal Perfusion in Heart Failure Patients With Reduced Ejection Fraction and Renal Impairment

NCT06611423

completedphase_1

Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427

NCT04630067

withdrawnphase_1

Study to Evaluate the Effects of AZD3427 in Patients With Heart Failure

NCT04890548

Clinical Trials (4)

Showing 4 of 4 trials

NCT05737940Phase 2

A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2

Completed

NCT06611423Phase 1

AZD3427 Effects on Renal Perfusion in Heart Failure Patients With Reduced Ejection Fraction and Renal Impairment

Terminated

NCT04630067Phase 1

Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427

Completed

NCT04890548Phase 1

Study to Evaluate the Effects of AZD3427 in Patients With Heart Failure

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4